Joshua K. Sabari, MD, is an associate professor in the Department of Medicine at New York University (NYU) Grossman School of Medicine. He is also medical director, ofThoracic Medical Oncology at NYU Langone Health’s Perlmutter Cancer Center.
Evaluating Efficacy Outcomes of TKI Therapies in KRAS G12C-Mutated NSCLC
June 18th 2025Panelists discuss how 2 FDA-approved KRAS G12C inhibitors (adagrasib and sotorasib) perform in second-line therapy after immunotherapy and chemotherapy, with both showing improved progression-free survival versus docetaxel despite modest gains, leading to their adoption as standard of care due to better tolerability profiles.
Read More
KRAS G12C-Mutated NSCLC: Current Treatment Paradigms
June 18th 2025Panelists discuss how critical broad-panel next-generation sequencing is for all patients with non–small cell lung cancer to enable biomarker-guided treatment, with focus on KRAS G12C mutations found in 12% to 14% of patients and consideration of PD-L1 expression levels and comutations when selecting frontline therapy.
Read More
Panelists discuss how medical professionals envision the future of early-stage non–small cell lung cancer (NSCLC) treatment evolving through the integration of novel therapies, predictive biomarkers, and personalized strategies to address current gaps in care, emphasizing the need for continued research to optimize outcomes and tailor interventions in resectable disease.
Read More
Advancements in the Management of Stage III NSCLC: Expert Insights on the LAURA Trial
June 5th 2025Panelists discuss how targeted therapy with osimertinib has revolutionized treatment approaches for unresectable early-stage non–small cell lung cancer (NSCLC) patients with EGFR mutations, offering new hope for a previously underserved patient population.
Read More
Expert Insights in the Management of Early-Stage NSCLC With Limited Nodal or Oligometastatic Disease
May 29th 2025Panelists discuss how advanced radiotherapy techniques, including stereotactic body radiation therapy (SBRT), combined with immunotherapy, have emerged as preferred treatment approaches for unresectable early-stage non–small cell lung cancer (NSCLC).
Read More
Expert Insights and Best Practices in the Diagnosis of Unresectable Early-Stage NSCLC
May 29th 2025Panelists discuss how the diagnostic workup for unresectable stage III non–small cell lung cancer (NSCLC) requires comprehensive staging including imaging studies (PET-CT, brain MRI), tissue sampling through bronchoscopy or endobronchial ultrasound (EBUS), molecular and biomarker testing, and multidisciplinary evaluation to guide optimal treatment planning.
Read More
Panelists discuss how to treat patients who do not achieve a pathological complete response or major pathological response after neoadjuvant chemoimmunotherapy, considering options such as adjuvant therapy, close surveillance, or clinical trial enrollment based on individual risk factors and disease characteristics.
Read More
Leveraging MRD Testing to Guide Treatment Decisions in Early-Stage Resectable NSCLC
May 21st 2025Panelists discuss how circulating tumor DNA could serve as a potential marker for minimal residual disease (MRD) in this setting, offering a noninvasive and sensitive method for monitoring treatment response and detecting relapse.
Read More
Evolving Targeted Therapy Approaches in Resectable Early-Stage NSCLC With Actionable Mutations
May 14th 2025Panelists discuss how medical professionals are integrating targeted therapies, such as those for EGFR, ALK, and other mutations like RET and ROS1, into the treatment of resectable early-stage non–small cell lung cancer (NSCLC), with a focus on incorporating the ADAURA and ALINA regimens into clinical practice.
Read More
Panelists discuss how medical professionals identify patients who should receive neoadjuvant immune checkpoint inhibitors (ICI) before surgery based on tumor characteristics, patient health, and treatment response, and how factors such as surgical outcomes, recurrence risk, and molecular markers guide decisions on the need for additional adjuvant therapy post surgery.
Read More
Panelists discuss how the latest efficacy and safety data from AEGEAN, CheckMate 816, CheckMate 77T, and KEYNOTE-671, along with recent approvals in early-stage non–small cell lung cancer (NSCLC) treatment, are shaping optimized treatment approaches and influencing clinical practice.
Read More
Enhancing Early-Stage NSCLC Diagnosis: Leveraging Pathology and Imaging for Accurate Staging
May 7th 2025Panelists discuss how a multidisciplinary team—including oncologists, thoracic surgeons, radiologists, and pathologists—collaborates to streamline the diagnostic process for patients with resectable non–small cell lung cancer (NSCLC), ensuring timely evaluation, accurate staging, and personalized treatment planning.
Read More
A Focus on the Role of Patient Navigators in the Diagnosis and Management of Early-Stage NSCLC
April 30th 2025Panelists discuss how a multidisciplinary team (MDT) approach to resectable non–small cell lung cancer (NSCLC) involves an initial diagnostic workup with imaging (CT, PET-CT), histologic confirmation via biopsy, staging with mediastinal assessment (endobronchial ultrasound or mediastinoscopy), and timely molecular testing (eg, EGFR, ALK, PD-L1) integrated early in the process to guide perioperative treatment decisions.
Read More
Panelists discuss how collaboration between pathologists, oncologists, and pulmonologists is essential for timely next-generation sequencing (NGS) testing in early-stage non–small cell lung cancer (NSCLC), emphasizing that molecular testing should ideally be ordered at diagnosis with prioritization of EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, and NTRK biomarkers to guide treatment decisions before surgical intervention.
Read More
Optimizing Tissue Biopsy and Disease Staging in Early-Stage NSCLC
April 16th 2025Panelists discuss how medical professionals frequently encounter tissue adequacy challenges in comprehensive genomic profiling for early-stage non–small cell lung cancer (NSCLC), employing strategies such as optimized biopsy techniques, efficient tissue triage protocols, and complementary liquid biopsies to ensure sufficient material for complete molecular analysis.
Read More
Panelists discuss how medical professionals currently approach molecular testing in early-stage non–small cell lung cancer (NSCLC) through comprehensive biomarker analysis, including targeted next-generation sequencing (NGS), to identify actionable mutations that guide adjuvant therapy decisions and improve patient outcomes.
Read More